深圳市理邦精密仪器股份有限公司 1、审议通过《2025 年半年度报告及其摘要》的议案 经审核，监事会认为：董事会编制和审议公司《2025 年半年度报告及其摘 要》的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完 整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司同日于巨潮资讯网（http://www.cninfo.com.cn） 披露的相关公 告。 表决结果：同意 3 票，反对 0 票，弃权 0 票，获得通过。 特此公告。 深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2025-034 深圳市理邦精密仪器股份有限公司 第六届监事会 2025年第二次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）第六届监事会 2025 年第二次会议于 2025 年 8 月 25 日（星期一）11:30 在深圳市坪山区坑梓街道金 沙社区金辉路 15 号理邦仪器工业园会议室召开，会议通知于 2025 年 8 月 14 日 以 ...

深圳市理邦精密仪器股份有限公司 2025 年半年度报告全文 0 深圳市理邦精密仪器股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人张浩、主管会计工作负责人祖幼冬及会计机构负责人(会计主 管人员)黄燕声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本公司请投资者认真阅读本半年度报告全文，并特别注意下列风险因素： 质量控制风险、管理风险、关税与汇率波动风险、新品市场竞争风险，具体 详见"第三节 管理层讨论与分析"之"十、公司面临的风险和应对措施"。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 1 一、载有法定代表人签名的 2025 年半年度报告原件； 二、载有法定代表人、主管会计工作负责人、会计机构负责人签名并盖章的财务报表； 三、报告期内在中国证监会指定网站上公开披露过的所有公司文件的正本及公告的原稿。 以上备查文件的备置地点：公司证券事务部办公室。 3 | ...

深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2025-033 深圳市理邦精密仪器股份有限公司 第六届董事会 2025 年第二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）第六届董事会 2025 年第二次会议于 2025 年 8 月 25 日（星期一）10:00 在深圳市坪山区坑梓街道金 沙社区金辉路 15 号理邦仪器工业园会议室召开，会议通知于 2025 年 8 月 14 日 以电子邮件方式发出。会议应出席董事 7 名，实际出席董事 7 名。本次会议召开 符合《公司法》及《公司章程》的相关规定。会议由董事长张浩先生主持，出席 会议的董事审议并通过记名投票方式表决通过了如下决议： 1、审议通过《2025 年半年度报告及其摘要》的议案 经审核，董事会认为公司编制的《2025 年半年度报告及其摘要》真实、准 确、完整，不存在任何虚假记载、误导性陈述或者重大遗漏。具体内容详见公司 同日于巨潮资讯网（http://www.cninfo.com.cn） 披露的相关 ...

Group 1 - The medical device industry experienced a slight increase of 0.07% on August 21, with a net outflow of 596 million yuan in main capital [1] - Among the component stocks, 55 stocks rose while 41 stocks fell [1] - The companies with the highest net outflow of main capital included Xinhua Medical (11.58 million yuan), Libang Instruments (10.77 million yuan), and Jiukang Bio (10.73 million yuan) [1] Group 2 - The latest prices and performance of selected medical companies include: Meihua Medical at 23.41 with an increase of 8.09% and a net inflow of 6.44 million yuan [2] - Mindray Medical at 245.71 with an increase of 3.87% and a net inflow of 879.86 million yuan [2] - Other notable companies include Yingke Medical at 37.43 with an increase of 1.08% and a net inflow of 599.81 million yuan, and Aibo Medical at 77.31 with an increase of 1.15% and a net inflow of 4360.64 million yuan [2]

Core Viewpoint - The introduction of a handheld ultrasound device by a Shenzhen-based company aims to improve maternal health in Africa, where access to ultrasound services is limited and often considered a luxury [1][2][3]. Group 1: Product Development and Market Potential - The company has completed Phase III clinical trials for its handheld ultrasound device and plans to deploy approximately 50 units in remote areas of Kenya for field testing [1][2]. - There is a significant demand for ultrasound services in Africa, with at least 4,000 secondary and tertiary hospitals in Kenya lacking such equipment, forcing pregnant women to travel long distances for care [2][3]. - The handheld ultrasound device is designed for community health workers without specialized training, utilizing deep learning technology to enhance accessibility in underserved areas [1][3]. Group 2: Health Statistics and Global Goals - Approximately 70% of global maternal deaths occur in sub-Saharan Africa, highlighting the urgent need for improved maternal healthcare solutions [2][3]. - The World Health Organization reports that in 2023, around 260,000 women died due to complications related to pregnancy or childbirth, emphasizing the critical need for preventive measures [2]. Group 3: Technological Innovation and Accessibility - The handheld ultrasound device can be operated by individuals with no medical background, requiring only six scans to complete an assessment, thus increasing diagnostic efficiency [3][5]. - The device connects directly to smartphones or tablets, making it easier to use and reducing the barriers to access [3][5]. Group 4: Strategic Expansion and Local Engagement - The company has been operating in Africa for over a decade and established its first office in Kenya in 2022, marking its commitment to the African market [7][8]. - Kenya serves as a strategic hub for the company due to its infrastructure development, financial systems, and potential for regional influence [7][8]. - The company aims to provide not only equipment but also ongoing support and training to local healthcare workers, ensuring sustainable healthcare improvements [9]. Group 5: Funding and Support from Global Initiatives - The Gates Foundation has recognized the potential of handheld ultrasound technology in improving maternal health in Africa and has invested significantly in its development [6]. - The foundation's support includes funding for AI obstetric ultrasound kits and collaborations with various healthcare companies to enhance deployment [6].

Core Insights - A significant portion of pregnant women in Africa, estimated at 30-40%, have never undergone any ultrasound screening, which places them at high risk during childbirth [1] - A Chinese company, Shenzhen RIBO, is set to change this situation with its innovative handheld ultrasound device, which has completed clinical trials and will be tested in remote areas of Kenya [1][2] - The handheld ultrasound device is designed for community health workers lacking professional ultrasound training, aiming to improve maternal and infant health in underdeveloped regions [1][3] Group 1: Market Demand and Challenges - The potential demand for ultrasound devices in Africa is substantial, with at least 4,000 secondary and tertiary hospitals in Kenya lacking such equipment [2] - Traditional ultrasound services are often inaccessible due to high costs and geographical barriers, forcing pregnant women to travel long distances for care [2] - The company aims to provide an affordable ultrasound solution leveraging "Chinese manufacturing" advantages, which can lower service costs and improve quality [2][3] Group 2: Technological Innovation - The handheld ultrasound device utilizes deep learning technology to assist non-medical personnel in efficiently screening for high-risk pregnancies [3] - The device can connect directly to smartphones or tablets, significantly lowering the barriers to access and operation [3] - The system requires only six scans to complete an examination, making it user-friendly even for those without a medical background [3] Group 3: Global Health Impact - The World Health Organization reports that approximately 70% of global maternal deaths occur in sub-Saharan Africa, highlighting the urgent need for improved maternal healthcare [2] - The Gates Foundation recognizes the potential of AI-powered handheld ultrasounds to revolutionize maternal health in Africa, potentially saving millions of lives by 2040 [5][6] Group 4: Company Strategy and Market Position - Shenzhen RIBO has been operating in Africa for over a decade, establishing a foothold through product exports and local partnerships [7] - The company’s overseas revenue has surged, accounting for 60% of total revenue, with a focus on expanding its presence in the African market [7] - Kenya is viewed as a strategic hub for further expansion into East Africa, supported by improved infrastructure and a developed financial system [7][8] Group 5: Local Engagement and Service - The company emphasizes the importance of localizing its strategy by training local technicians and providing tailored services to build customer loyalty [9] - Continuous maintenance and rapid repair of medical equipment are critical in regions with weak infrastructure, and the company aims to enhance service responsiveness by establishing Kenya as its operational center [9]

Core Viewpoint - The company, Lifetech Scientific Corporation, is currently facing a decline in stock price and performance metrics, with a PE ratio lower than the industry average, indicating potential undervaluation in the medical device sector [1][2]. Company Summary - Lifetech Scientific Corporation's stock closed at 13.07 yuan, down 2.83%, with a rolling PE ratio of 40.15 times and a total market capitalization of 7.576 billion yuan [1]. - The company operates in the medical device sector, focusing on the research, production, sales, and service of medical electronic devices and in vitro diagnostic products [1]. - Key products include critical care monitoring solutions, bedside monitoring solutions, smart vital sign management solutions, various ECG and ultrasound systems, and molecular diagnostic products [1]. Financial Performance - For the first quarter of 2025, the company reported revenue of 420 million yuan, a year-on-year decrease of 5.25%, while net profit was 65.0882 million yuan, reflecting a year-on-year increase of 68.98% [1]. - The sales gross margin stood at 58.34% [1]. Industry Summary - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, positioning Lifetech Scientific Corporation at the 78th rank within the industry [1][2]. - The company is held by four institutions, all of which are funds, with a total holding of 55,200 shares valued at 0.01 million yuan [1].

8月11日，理邦仪器今日收盘13.38元，上涨1.44%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到41.11倍，创116天以来新低，总市值77.56亿元。 深圳市理邦精密仪器股份有限公司的主营业务是从事医疗电子设备产品和体外诊断产品的研发、生产、 销售、服务。公司的主要产品是急危重症监护方案、床旁监护方案、智能生命体征查房方案、静态心 电、运动心电、动态心电/血压、心电网络解决方案、推车式全数字彩色超声诊断系统、便携式全数字 彩色超声诊断系统、全数字超声诊断系统、手持式超声诊断系统、围产监护方案、妇科诊疗方案、盆底 康复方案、血气分析仪、采血器、软件管理产品、磁敏荧光免疫分析仪、血细胞分析仪、分子诊断产 品、智慧健康业务。 最新一期业绩显示，2025年一季报，公司实现营业收入4.20亿元，同比-5.25%；净利润6508.82万元，同 比68.98%，销售毛利率58.34%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13理邦仪器41.1147.843.7477.56亿行业平均 56.5652.664.92118.97亿行业中值39.7639.192.9457.67亿1九安医疗 ...

Core Insights - Suzhou Duying Medical Technology Co., Ltd. has been established with a registered capital of 1 million yuan, focusing on the production of Class II medical devices, AI application software development, big data services, and information system integration services [1][2]. Company Information - The legal representative of Suzhou Duying Medical Technology Co., Ltd. is Shen Yanhong, and the company is fully owned by Shenzhen Duying Medical Technology Co., Ltd. [1][3]. - The company is registered in Suzhou, Jiangsu Province, and its business scope includes the production of second-class medical devices and third-class medical devices, subject to approval [2][3]. - The company is classified under the specialized equipment manufacturing industry (C35) [2]. Shareholding Structure - Shenzhen Duying Medical Technology Co., Ltd. holds 100% of Suzhou Duying Medical Technology Co., Ltd. with a registered capital of 1 million yuan [3]. - Shen Yanhong owns 57.40% of Shenzhen Duying Medical Technology Co., Ltd., contributing 5.07 million yuan, while Shenzhen Liyang Precision Instrument Co., Ltd. holds 23.84% with a contribution of 2.106 million yuan [3].

Core Insights - The company, Lifesense Medical, closed at 13.09 yuan on July 28, with a 1.71% increase, and a rolling PE ratio of 40.22, marking a new low in 104 days, with a total market capitalization of 7.588 billion yuan [1][2] - The average PE ratio in the medical device industry is 55.28, with a median of 38.06, placing Lifesense Medical at the 79th position in the industry ranking [1][2] - As of the first quarter of 2025, four institutions held shares in Lifesense Medical, with a total of 55,200 shares valued at 0.01 million yuan [1] Company Overview - Lifesense Medical specializes in the research, development, production, sales, and service of medical electronic devices and in vitro diagnostic products [1] - Key products include critical care monitoring solutions, bedside monitoring solutions, intelligent vital signs management solutions, various ECG systems, ultrasound diagnostic systems, perinatal monitoring solutions, gynecological diagnostic solutions, blood gas analyzers, and molecular diagnostic products [1] Financial Performance - For the first quarter of 2025, the company reported revenue of 420 million yuan, a year-on-year decrease of 5.25%, while net profit was 65.0882 million yuan, reflecting a year-on-year increase of 68.98% [2] - The sales gross margin stood at 58.34% [2]